Echo IQ Limited (ASX:EIQ)
Australia
· Delayed Price · Currency is AUD | Market Cap | 650.95M |
| Revenue (ttm) | 90.91K |
| Net Income (ttm) | -15.71M |
| Shares Out | 660.86M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,339,138 |
| Average Volume | 3,036,913 |
| Open | 1.215 |
| Previous Close | 1.145 |
| Day's Range | 0.975 - 1.240 |
| 52-Week Range | 0.165 - 1.350 |
| Beta | 0.24 |
| RSI | 51.09 |
| Earnings Date | May 27, 2026 |
About Echo IQ
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is based in Claremont, Australia. [Read more]
Financial Performance
In fiscal year 2025, Echo IQ's revenue was 101,409, an increase of 127.89% compared to the previous year's 44,500. Losses were -13.26 million, 145.2% more than in 2024.
Financial StatementsNews
Echo IQ Transcript: Life Sciences Virtual Investor Forum 2025
AI-powered echocardiogram diagnostics are driving rapid commercialization, with FDA clearance for aortic stenosis achieved and heart failure submission underway. Major hospital integrations, a robust product pipeline, and a SaaS model set the stage for significant revenue growth and a potential U.S. IPO in 2026.
Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Echo IQ Transcript: Piper Sandler 37th Annual Healthcare Conference
A novel AI platform enables real-time, highly accurate diagnosis of heart disease from echocardiogram data, with FDA-cleared aortic stenosis detection and a heart failure solution nearing submission. Integration with major hospitals and strong clinical validation support rapid U.S. expansion and revenue growth in 2026.
Echo IQ Transcript: Status Update
EchoSolve HF achieved 99.5% sensitivity and 91% specificity in a major Mayo Clinic validation, supporting imminent FDA submission and large-scale US commercialization. The platform targets significant unmet needs in heart failure and aortic stenosis, with a robust pipeline and global expansion plans.
Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
SYDNEY, Nov. 24, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise that it has completed its clinical validation f...
Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
SYDNEY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ), today announced that Dustin Haines, Chief Executive Officer, will participa...